71
|
Association of the level of heteroplasmy of the 15059G>A mutation in the MT-CYB mitochondrial gene with essential hypertension.
Sobenin IA, Chistiakov DA, Sazonova MA, Ivanova MM, Bobryshev YV, Orekhov AN, Postnov AY.
World J Cardiol. 2013 May 26;5(5):132-40. doi: 10.4330/wjc.v5.i5.132.
|
72
|
Changes of lysosomes in the earliest stages of the development of atherosclerosis.
Bobryshev YV, Shchelkunova TA, Morozov IA, Rubtsov PM, Sobenin IA, Orekhov AN, Smirnov AN.
J Cell Mol Med. 2013 May;17(5):626-35. doi: 10.1111/jcmm.12042. Epub 2013 Mar 14.
|
73
|
Blood Atherogenicity as a Target for Anti-atherosclerotic Therapy.
Sobenin IA, Chistiakov DA, Bobryshev YV, Orekhov AN.
Curr Pharm Des. 2013;19(33):5954-62.
|
74
|
Mitochondrial mutations in atherosclerosis: new solutions in research and possible clinical applications.
Sobenin IA, Chistiakov DA, Bobryshev YV, Postnov AY, Orekhov AN.
Curr Pharm Des. 2013;19(33):5942-53.
|
75
|
Direct anti-atherosclerotic therapy; development of natural anti-atherosclerotic drugs preventing cellular cholesterol retention.
Orekhov AN.
Curr Pharm Des. 2013;19(33):5909-28.
|
76
|
Vascular extracellular matrix in atherosclerosis.
Chistiakov DA, Sobenin IA, Orekhov AN.
Cardiol Rev. 2013 Nov-Dec;21(6):270-88. doi: 10.1097/CRD.0b013e31828c5ced.
|
77
|
Regulatory T cells in atherosclerosis and strategies to induce the endogenous atheroprotective immune response.
Chistiakov DA, Sobenin IA, Orekhov AN.
Immunol Lett. 2013 Mar;151(1-2):10-22. doi: 10.1016/j.imlet.2013.01.014. Epub 2013 Feb 11.
|
78
|
Changes of mitochondria in atherosclerosis: possible determinant in the pathogenesis of the disease.
Sobenin IA, Sazonova MA, Postnov AY, Bobryshev YV, Orekhov AN.
Atherosclerosis. 2013 Apr;227(2):283-8. doi: 10.1016/j.atherosclerosis.2013.01.006. Epub 2013 Jan 25.
|
79
|
Anti-atherosclerotic therapy based on botanicals.
Orekhov AN, Sobenin IA, Korneev NV, Kirichenko TV, Myasoedova VA, Melnichenko AA, Balcells M, Edelman ER, Bobryshev YV.
Recent Pat Cardiovasc Drug Discov. 2013 Apr;8(1):56-66.
|